Foghorn Total Assets from 2010 to 2025

FHTX Stock

USD 4.34 0.36 9.05%

Foghorn Therapeutics Total Assets yearly trend continues to be fairly stable with very little volatility. Total Assets will likely drop to about 280.8 M in 2025. Total Assets is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. View All Fundamentals

Total Assets

First Reported

2010-12-31

Previous Quarter

328.8 M

Current Value

280.8 M

Quarterly Volatility

163.1 M

Credit Downgrade

Yuan Drop

Covid

Check Foghorn Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Foghorn Therapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 12.8 M, Interest Income of 12.8 M or Depreciation And Amortization of 3.9 M, as well as many indicators such as Price To Sales Ratio of 8.66, Dividend Yield of 0.0 or Days Sales Outstanding of 66.4 K. Foghorn financial statements analysis is a perfect complement when working with Foghorn Therapeutics Valuation or Volatility modules.

Check out the analysis of Foghorn Therapeutics Correlation against competitors.

For more information on how to buy Foghorn Stock please use our How to Invest in Foghorn Therapeutics guide.

Latest Foghorn Therapeutics' Total Assets Growth Pattern

Below is the plot of the Total Assets of Foghorn Therapeutics over the last few years. Total assets refers to the total amount of Foghorn Therapeutics assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in Foghorn Therapeutics books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. It is the total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets. Foghorn Therapeutics' Total Assets historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Foghorn Therapeutics' overall financial position and show how it may be relating to other accounts over time.

View

Last Reported 285.92 M

10 Years Trend

Slightly volatile

Compare to Others All Fundamentals

Total Assets

Timeline

Foghorn Total Assets Regression Statistics

	Arithmetic Mean	155,351,355
	Geometric Mean	89,225,883
	Coefficient Of Variation	105.01
	Mean Deviation	142,956,194
	Median	43,058,000
	Standard Deviation	163,128,798
	Sample Variance	26611T
	Range	497.4M
	R-Value	0.75
	Mean Square Error	12342.5T
	R-Squared	0.57
	Significance	0.0008
	Slope	25,802,995
	Total Sum of Squares	399165.1T

Foghorn Total Assets History

	2025	280.8 M
	2024	328.8 M
	2023	285.9 M
	2022	404.9 M
	2021	519.8 M
	2020	255.6 M
	2019	22.3 M

Other Fundumenentals of Foghorn Therapeutics

Intangibles To Total Assets

Foghorn Therapeutics Total Assets component correlations

	Total Assets	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Long Term Debt	Total Liab	Net Invested Capital	Total Current Assets	Net Working Capital	Common Stock	Property Plant Equipment	Current Deferred Revenue	Short Long Term Debt	Short Term Debt	Net Receivables	Short Term Investments	Capital Surpluse
Total Assets		0.42	0.72	-0.44	-0.83	0.77	0.91	0.93	0.41	1.0	0.99	0.93	0.93	0.53	-0.32	0.99	0.6	0.48	0.78
Total Stockholder Equity	0.42		0.85	-0.11	0.06	-0.08	0.33	0.07	0.99	0.4	0.46	0.34	0.45	0.08	0.33	0.35	0.52	-0.21	-0.18
Net Tangible Assets	0.72	0.85		-0.06	-0.41	0.36	0.69	0.43	0.86	0.69	0.72	0.73	0.8	0.11	-0.08	0.64	0.51	0.02	0.29
Net Debt	-0.44	-0.11	-0.06		0.36	-0.32	-0.32	-0.46	-0.06	-0.44	-0.45	-0.34	-0.29	-0.98	-0.08	-0.46	0.01	-0.82	-0.33
Retained Earnings	-0.83	0.06	-0.41	0.36		-0.95	-0.87	-0.92	0.06	-0.82	-0.77	-0.9	-0.85	-0.49	0.55	-0.82	-0.18	-0.68	-0.93
Accounts Payable	0.77	-0.08	0.36	-0.32	-0.95		0.91	0.88	-0.07	0.75	0.68	0.89	0.84	0.47	-0.45	0.73	0.09	0.68	0.92
Long Term Debt	0.91	0.33	0.69	-0.32	-0.87	0.91		0.88	0.34	0.88	0.85	0.98	0.98	0.46	-0.29	0.85	0.35	0.53	0.8
Total Liab	0.93	0.07	0.43	-0.46	-0.92	0.88	0.88		0.06	0.93	0.9	0.88	0.83	0.57	-0.37	0.93	0.47	0.61	0.92
Net Invested Capital	0.41	0.99	0.86	-0.06	0.06	-0.07	0.34	0.06		0.39	0.45	0.35	0.46	0.05	0.28	0.34	0.49	-0.21	-0.16
Total Current Assets	1.0	0.4	0.69	-0.44	-0.82	0.75	0.88	0.93	0.39		1.0	0.91	0.9	0.53	-0.31	0.99	0.63	0.47	0.78
Net Working Capital	0.99	0.46	0.72	-0.45	-0.77	0.68	0.85	0.9	0.45	1.0		0.88	0.88	0.53	-0.28	0.99	0.68	0.43	0.72
Common Stock	0.93	0.34	0.73	-0.34	-0.9	0.89	0.98	0.88	0.35	0.91	0.88		0.99	0.46	-0.39	0.88	0.34	0.55	0.83
Property Plant Equipment	0.93	0.45	0.8	-0.29	-0.85	0.84	0.98	0.83	0.46	0.9	0.88	0.99		0.42	-0.34	0.87	0.38	0.47	0.76
Current Deferred Revenue	0.53	0.08	0.11	-0.98	-0.49	0.47	0.46	0.57	0.05	0.53	0.53	0.46	0.42		-0.03	0.55	-0.01	0.89	0.45
Short Long Term Debt	-0.32	0.33	-0.08	-0.08	0.55	-0.45	-0.29	-0.37	0.28	-0.31	-0.28	-0.39	-0.34	-0.03		-0.4	0.09	-0.33	-0.62
Short Term Debt	0.99	0.35	0.64	-0.46	-0.82	0.73	0.85	0.93	0.34	0.99	0.99	0.88	0.87	0.55	-0.4		0.63	0.49	0.79
Net Receivables	0.6	0.52	0.51	0.01	-0.18	0.09	0.35	0.47	0.49	0.63	0.68	0.34	0.38	-0.01	0.09	0.63		-0.29	0.2
Short Term Investments	0.48	-0.21	0.02	-0.82	-0.68	0.68	0.53	0.61	-0.21	0.47	0.43	0.55	0.47	0.89	-0.33	0.49	-0.29		0.66
Capital Surpluse	0.78	-0.18	0.29	-0.33	-0.93	0.92	0.8	0.92	-0.16	0.78	0.72	0.83	0.76	0.45	-0.62	0.79	0.2	0.66

Click cells to compare fundamentals

About Foghorn Therapeutics Financial Statements

Foghorn Therapeutics investors use historical fundamental indicators, such as Foghorn Therapeutics' Total Assets, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Foghorn Therapeutics. Please read more on our technical analysis and fundamental analysis pages.

		Last Reported	Projected for Next Year
	Total Assets	328.8 M	280.8 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
GM	General Motors
S	SentinelOne

Additional Tools for Foghorn Stock Analysis

When running Foghorn Therapeutics' price analysis, check to measure Foghorn Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Foghorn Therapeutics is operating at the current time. Most of Foghorn Therapeutics' value examination focuses on studying past and present price action to predict the probability of Foghorn Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Foghorn Therapeutics' price. Additionally, you may evaluate how the addition of Foghorn Therapeutics to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC